NTSR2 Antibody

What is NTSR2 and why is it significant in neuroscience research?

NTSR2 (neurotensin receptor type 2, also known as NTR2 or NT-R-2) is a G-protein coupled receptor that binds neurotensin, a 13-amino acid neuropeptide involved in various physiological processes including pain modulation, thermoregulation, and dopaminergic signaling. The receptor has a molecular mass of approximately 45.4 kilodaltons and is expressed in various regions of the central nervous system. NTSR2's significance stems from its potential role as a therapeutic target for neurological and psychiatric disorders, particularly those involving dopaminergic pathways . Understanding NTSR2 function requires reliable antibodies for detection, localization, and functional studies that can distinguish it from the related NTSR1 receptor. Research has shown that NTSR2 expression varies with age, adding complexity to developmental studies of this receptor .

How do I select the appropriate NTSR2 antibody for my specific research application?

Selecting the optimal NTSR2 antibody depends on multiple experimental considerations:

• Target species compatibility: Ensure the antibody recognizes NTSR2 in your experimental model (human, mouse, rat, etc.). Cross-reactivity information should be verified in manufacturer specifications .

• Application requirements: Different applications require antibodies validated for specific techniques:

  • Western blot: Select antibodies demonstrated to detect denatured NTSR2

  • Immunohistochemistry: Choose antibodies proven effective in fixed tissue sections

  • Immunofluorescence: Verify antibodies work in your fixation conditions

  • ELISA: Ensure antibodies recognize native protein conformation

• Epitope consideration: Antibodies targeting different regions of NTSR2 may perform differently. C-terminal antibodies may access different epitopes than those targeting internal regions .

• Validation evidence: Prioritize antibodies with published validation data, especially those with knockout controls that demonstrate specificity .

• Conjugation needs: Determine whether you require unconjugated antibodies or those conjugated to specific tags (FITC, biotin, HRP) based on your detection system .

Review antibody datasheets thoroughly and consult literature using these reagents before selection.

What are the primary differences between NTSR1 and NTSR2 antibodies in experimental systems?

NTSR1 and NTSR2 antibodies target distinct neurotensin receptor subtypes that have different pharmacological properties, tissue distributions, and signaling mechanisms. Key experimental distinctions include:

• Specificity challenges: Due to structural similarities between the receptors, antibody cross-reactivity must be carefully evaluated. Validation using receptor-specific knockout models is considered the gold standard for confirming specificity .

• Expression pattern differences: NTSR1 and NTSR2 show distinct expression patterns, with NTSR2 having greater representation in particular brain regions. Proper controls are essential when interpreting immunohistochemical data .

• Developmental considerations: Expression of both receptors varies with age, so experimental timing is critical. NTSR2 antibodies may detect different signal intensities depending on developmental stage .

• Pharmacological interactions: When using antibodies alongside receptor antagonists, researchers should note that some compounds (like SR48692) intended to block NTSR1 also function as NTSR2 agonists, potentially complicating data interpretation .

• Functional differences: Since these receptors couple to different signaling pathways, antibodies that block receptor function may produce distinct physiological effects depending on which receptor is targeted.

What validation methods should I use to confirm NTSR2 antibody specificity?

Rigorous validation is essential for confident interpretation of NTSR2 antibody results. Recommended validation approaches include:

• Genetic controls: Testing antibodies on tissues from NTSR2 knockout mice provides the most definitive specificity control. Absence of signal in knockout tissue strongly supports antibody specificity .

• Peptide competition: Pre-incubating the antibody with excess immunizing peptide should eliminate specific staining in Western blot or immunohistochemistry.

• Multiple antibody concordance: Using different antibodies targeting distinct NTSR2 epitopes to confirm consistent staining patterns increases confidence in specificity.

• Expression correlation: Comparing antibody staining with in situ hybridization data for NTSR2 mRNA can help validate detection patterns.

• Heterologous expression: Testing antibodies on cells transfected with NTSR2 versus empty vector or NTSR1-transfected controls provides another specificity measure.

• Cross-reactivity assessment: Evaluating potential cross-reactivity with NTSR1 using parallel NTSR1 knockout controls helps distinguish between these related receptors .

• Western blot molecular weight verification: Confirming the detected protein band matches NTSR2's expected molecular weight (~45.4 kDa) supports proper target identification .

How can I optimize NTSR2 antibody-based detection in fixed brain tissue sections?

Optimizing NTSR2 immunodetection in brain tissue requires addressing several technical challenges:

• Fixation protocol adjustment: NTSR2 epitopes can be sensitive to overfixation. Consider these approaches:

  • Test paraformaldehyde concentrations between 2-4%

  • Compare post-fixation times (4-24 hours) to determine optimal preservation

  • For some antibodies, light fixation followed by freeze-substitution may better preserve antigenicity

• Antigen retrieval optimization:

  • Heat-mediated retrieval using citrate buffer (pH 6.0) for 10-20 minutes

  • Enzymatic retrieval with proteinase K (1-5 μg/ml, 5-15 minutes)

  • Test multiple retrieval methods systematically with positive control tissue

• Signal amplification strategies:

  • Tyramide signal amplification can enhance detection of low abundance NTSR2

  • Biotinylated secondary antibodies with avidin-biotin complex (ABC) enhancement

  • Consider polymer-based detection systems for improved signal-to-noise ratio

• Background reduction techniques:

  • Extended blocking (2-4 hours) with serum matching secondary antibody host

  • Addition of 0.1-0.3% Triton X-100 for improved antibody penetration

  • Use of carrier proteins (1-2% BSA or 0.2% gelatin) in diluent

  • Pre-absorption of secondary antibodies with tissue powder

• Incubation optimization:

  • Extended primary antibody incubation (24-72 hours at 4°C)

  • Careful titration of antibody concentration to maximize signal while minimizing background

  • Serial sectioning with ascending/descending antibody concentrations to identify optimal working dilution

Include validation controls with each experiment, particularly comparing staining patterns to NTSR2 knockout tissue when available .

What strategies can address cross-reactivity issues between NTSR1 and NTSR2 antibodies?

Distinguishing between these related receptors requires specialized approaches:

• Computational epitope analysis: Before selecting antibodies, analyze sequence divergence between NTSR1 and NTSR2 to identify unique epitopes with minimal homology.

• Differential expression screening: Test antibodies in tissues known to differentially express NTSR1 versus NTSR2 to evaluate potential cross-reactivity.

• Receptor-selective knockdown validation:

  • Use siRNA or shRNA to selectively reduce NTSR2 expression

  • Confirm corresponding reduction in antibody signal

  • Test remaining signal with NTSR1-selective knockdown

• Dual immunolabeling approach:

  • Perform co-localization studies with independently validated NTSR1 and NTSR2 antibodies

  • Use antibodies raised in different host species

  • Analyze co-localization patterns quantitatively

• Pharmacological discrimination:

  • Pre-treatment with selective ligands that internalize each receptor type

  • Recently developed NTSR2-selective antagonists can help pharmacologically distinguish receptor populations

• Heterologous expression system calibration:

  • Test antibodies on cells expressing controlled ratios of NTSR1:NTSR2

  • Develop standardized signal intensity calibration curves

  • Use these to interpret signals in experimental samples

• Genetic models: When available, use tissue from NTSR1 knockout, NTSR2 knockout, and double knockout models to create a definitive antibody specificity profile .

How can I design experiments to study developmental changes in NTSR2 expression using antibodies?

Experimental design for developmental NTSR2 studies requires careful consideration of age-dependent expression patterns :

• Age-comprehensive sampling:

  • Establish a systematic timeline covering key developmental stages

  • Include embryonic (E14, E16, E18), early postnatal (P0, P7, P14, P21), adolescent (P28-P42), and adult (>P60) timepoints

  • Maintain consistent tissue processing protocols across all timepoints

• Quantitative analysis workflow:

  • Standardize image acquisition parameters (exposure, gain, offset)

  • Implement automated region-of-interest analysis to reduce bias

  • Use fluorescence intensity calibration standards to normalize between imaging sessions

  • Apply consistent thresholding algorithms for signal quantification

• Parallel validation approaches:

  • Correlate protein detection (antibody) with mRNA expression (qPCR, in situ hybridization)

  • Include western blot quantification alongside immunohistochemistry

  • Track both total protein levels and subcellular localization changes

• Genetic labeling strategies:

  • Consider using NTSR2 reporter mouse lines to complement antibody detection

  • Dual recombinase systems (FlpO-induced IRES-Cre) in NTSR2-expressing cells can provide genetic access to these populations

• Statistical considerations:

  • Power analysis to determine appropriate sample size across development

  • Implement mixed linear models for longitudinal data analysis

  • Account for regional heterogeneity in expression patterns

• Technical controls:

  • Include tissue from NTSR2 knockout animals at each developmental timepoint

  • Process and image all samples in parallel to minimize batch effects

  • Validate antibody lot consistency throughout longitudinal studies

What techniques combine NTSR2 antibodies with functional assays to study receptor signaling?

Integrating NTSR2 detection with functional assays provides deeper insights into receptor biology:

• Proximity ligation assays (PLA):

  • Detect protein-protein interactions between NTSR2 and downstream signaling molecules

  • Requires antibodies from different host species targeting NTSR2 and interaction partners

  • Provides spatial resolution of interaction events within cells

• Phospho-specific antibody approaches:

  • Use phospho-state specific antibodies to downstream signaling molecules (ERK1/2, Akt)

  • Correlate with NTSR2 activation using dual immunofluorescence

  • Enables temporal analysis of signaling cascade activation

• Antibody-based receptor internalization assays:

  • Surface labeling of NTSR2 under non-permeabilizing conditions

  • Stimulation with agonists followed by temperature shifts to permit internalization

  • Differential labeling of remaining surface receptors to quantify internalization rates

• Calcium imaging with immunocytochemistry:

  • Perform calcium imaging in NTSR2-expressing cells identified by live-cell compatible antibodies

  • Fix and perform post-hoc immunostaining to correlate functional responses with receptor expression levels

  • Quantify relationship between receptor density and signaling magnitude

• Antibody-mediated receptor modulation:

  • Function-blocking antibodies targeting extracellular NTSR2 domains

  • Correlate blockade efficacy with receptor expression levels

  • Combine with electrophysiological recordings in specific neuronal populations

• BRET/FRET biosensor integration:

  • Create fusion proteins combining NTSR2 with BRET/FRET biosensors

  • Validate fusion protein detection with NTSR2 antibodies

  • Correlate receptor conformational changes with downstream signaling events

What are common causes of false positive signals with NTSR2 antibodies and how can they be addressed?

• Cross-reactivity with NTSR1:

  • Validate with NTSR2 knockout tissue as negative control

  • Pre-absorb antibody with recombinant NTSR1 protein

  • Compare staining pattern with known NTSR1 versus NTSR2 distribution

• Non-specific binding to hydrophobic domains:

  • Include additional blocking agents (0.1-0.3% Triton X-100, 0.2% gelatin)

  • Increase BSA concentration in blocking buffer (3-5%)

  • Pre-clear antibody with acetone powder from target tissue

• Fc receptor interactions:

  • Include normal serum from antibody host species

  • Add commercial Fc receptor blocking reagents

  • Use F(ab')2 antibody fragments to eliminate Fc portions

• Endogenous peroxidase/phosphatase activity:

  • Implement appropriate quenching steps (3% H₂O₂, 30 minutes)

  • Use levamisole for alkaline phosphatase quenching

  • Confirm quenching efficacy with enzyme-only controls

• Endogenous biotin interference:

  • Implement avidin-biotin blocking steps when using biotinylated detection

  • Consider switching to polymer-based detection systems

  • Use streptavidin-based detection with enhanced washing

• Fixation artifacts:

  • Test multiple fixation protocols with proper positive controls

  • Implement graded ethanol fixation series

  • Consider cryo-substitution methods for membrane proteins

For each potential source, implement systematic comparative controls to identify and eliminate the specific cause of false positives in your experimental system.

How can I optimize Western blot protocols specifically for NTSR2 detection?

NTSR2 Western blot optimization requires addressing the challenges of membrane protein detection:

• Sample preparation refinements:

  • Use specialized membrane protein extraction buffers containing:

    • 1% NP-40 or Triton X-100

    • 0.5% sodium deoxycholate

    • Protease inhibitor cocktail with emphasis on membrane proteases

  • Avoid boiling samples (heat to 37-50°C for 10 minutes instead)

  • Include 100 mM DTT or 5% β-mercaptoethanol to fully reduce disulfide bonds

• Gel selection and transfer optimization:

  • Use gradient gels (4-15% or 4-20%) to optimize resolution around 45.4 kDa

  • Extended transfer times (overnight at 30V at 4°C)

  • Consider semi-dry transfer systems with specialized buffers for membrane proteins

  • Use PVDF membranes with 0.2 μm pore size for improved retention

• Blocking and antibody incubation:

  • Test alternative blocking agents:

    • 5% non-fat dry milk

    • 3-5% BSA

    • Commercial membrane protein-optimized blockers

  • Extended primary antibody incubation (overnight at 4°C with gentle rocking)

  • Dilute antibodies in blocking buffer with 0.05-0.1% Tween-20

• Signal detection enhancement:

  • Use high-sensitivity ECL substrates with extended exposure times

  • Consider signal amplification systems (biotin-streptavidin)

  • Implement digital imaging with cumulative exposure functionality

• Validation controls:

  • Include positive control (brain tissue lysate)

  • Run NTSR2-transfected cell lysate alongside non-transfected control

  • When available, include NTSR2 knockout tissue as negative control

• Quantification considerations:

  • Normalize to membrane protein loading controls (Na⁺/K⁺-ATPase)

  • Perform linear range determination for antibody concentration

  • Use total protein normalization methods (stain-free gels or REVERT total protein stain)

How do post-translational modifications affect NTSR2 antibody recognition and how can this be experimentally controlled?

Post-translational modifications (PTMs) can significantly impact antibody epitope recognition. For NTSR2:

• Common PTMs affecting detection:

  • Phosphorylation: NTSR2 contains multiple phosphorylation sites

  • Glycosylation: N-linked glycosylation occurs in the extracellular domain

  • Palmitoylation: Affects membrane insertion and trafficking

  • Ubiquitination: Regulates receptor turnover

• Experimental strategies to address PTM variability:

  • Phosphorylation analysis:

    • Phosphatase treatment of parallel samples

    • Comparison of detection before/after treatment

    • Use of phosphorylation state-specific antibodies when available

  • Glycosylation assessment:

    • Enzymatic deglycosylation (PNGase F, Endo H)

    • Compare migration patterns before/after treatment

    • Select antibodies targeting non-glycosylated epitopes

  • Combined biochemical approach:

    • Systematically apply PTM-removing enzymes

    • Create a "PTM profile" of antibody sensitivity

    • Select application-appropriate antibodies based on PTM sensitivity

• Workflow for evaluating PTM impact:

  • Split samples and subject to specific PTM-modifying treatments

  • Process in parallel through detection workflow

  • Quantitatively compare signal intensity and pattern

  • Document PTM sensitivity for specific antibody lots

• Data interpretation guidelines:

  • Consider physiological state influence on PTM status

  • Account for regional and developmental differences in PTM patterns

  • Implement consistent sample processing to maintain PTM status

• Specialized controls:

  • Create expression constructs with PTM site mutations

  • Compare antibody recognition across mutant series

  • Develop standardized positive controls with defined PTM status

What are best practices for multiplexing NTSR2 antibodies with other neural markers?

Multiplexed detection enables contextual analysis of NTSR2 expression within neural circuits:

• Antibody selection criteria for multiplexing:

  • Host species compatibility (select primary antibodies from different species)

  • Fixation and retrieval condition alignment

  • Similar working dilution ranges to simplify protocols

  • Validated performance in multiplexed conditions

• Technical optimization approaches:

  • Sequential detection strategy:

    • Complete first primary-secondary detection

    • Apply stringent stripping/blocking between rounds

    • Proceed with subsequent antibody pairs

    • Include controls for incomplete stripping

  • Simultaneous incubation refinement:

    • Pre-test for cross-reactivity between all reagents

    • Optimize blocking for minimal background across all antibodies

    • Balance working concentrations to achieve comparable signal intensities

    • Use directly conjugated primary antibodies when possible

• Signal separation methods:

  • Spectral unmixing for fluorescent detection

  • Sequential chromogenic development with different substrates

  • Antibody pre-labeling with distinguishable nanoparticles

  • Super-resolution approaches for subcellular co-localization studies

• Controls for multiplexed detection:

  • Single antibody controls processed alongside multiplex samples

  • Secondary-only controls for each detection channel

  • Absorption controls verifying specificity in multiplex context

  • Serial sections with reversed detection order

• Analysis considerations:

  • Implement co-localization algorithms with appropriate statistical tests

  • Account for chromatic aberration in co-localization studies

  • Use standardized thresholding methods across experiments

  • Apply tissue clearing techniques for improved 3D analysis of co-expression

How can I combine NTSR2 antibodies with tissue clearing techniques for whole-brain receptor mapping?

Whole-brain NTSR2 mapping benefits from integrating antibody detection with tissue clearing:

• Compatibility assessment of NTSR2 antibodies with clearing protocols:

  • Test antibody performance across major clearing approaches:

    • Solvent-based (3DISCO, iDISCO+)

    • Aqueous-based (CLARITY, CUBIC)

    • Hydrogel-based (PACT, SHIELD)

  • Optimize antibody concentration for each clearing method

  • Determine penetration depth limitations for whole-mount detection

• Protocol adaptation for optimal NTSR2 detection:

  • Extended antibody incubation times (3-14 days at 37°C)

  • Implement active antibody delivery methods:

    • Centrifugal force

    • Electrophoresis-assisted penetration

    • Pressure perfusion systems

  • Use smaller antibody fragments (Fab, nanobodies) when available

• Signal amplification strategies for volume imaging:

  • Tyramide signal amplification compatible with clearing

  • Chain reaction amplification approaches

  • Antibody-DNA conjugates with hybridization chain reaction amplification

  • Signal-anchoring methods to prevent diffusion during clearing

• 3D imaging optimization:

  • Light-sheet microscopy parameter optimization for NTSR2 signal

  • Working distance and refractive index matching considerations

  • Tiling and stitching approaches for whole-brain datasets

  • Resolution enhancement through deconvolution algorithms

• Quantitative analysis workflows:

  • Registration to standardized brain atlases

  • Automated detection and counting of NTSR2-positive cells

  • Density mapping across neuroanatomical regions

  • Comparative analysis between experimental conditions

• Validation approaches:

  • Correlative thin-section immunohistochemistry

  • Region-specific verification with traditional methods

  • Genetic reporter correlation for expression confirmation

What approaches combine genetic tools with NTSR2 antibodies for functional circuit mapping?

Integrating genetic approaches with antibody detection enables multidimensional analysis:

• Dual recombinase-based genetic access to NTSR2 neurons:

  • FlpO-dependent IRES-Cre expression in NTSR2 cells enables selective manipulation

  • Cre-dependent reporters or effectors permit functional studies

  • Combine with antibody detection to verify genetic targeting fidelity

• Viral-genetic intersection strategies:

  • Retrograde tracing from projection targets of NTSR2 neurons

  • Anterograde trans-synaptic tracing from NTSR2 input sources

  • Validation of connectivity with NTSR2 antibody co-labeling

• Activity-dependent genetic tagging with antibody validation:

  • TRAP or E-SARE approaches to identify activated NTSR2 neurons

  • Targeted recombination in active populations (TRAP) within NTSR2 circuits

  • Antibody co-labeling to confirm receptor expression in functionally identified neurons

• In vivo calcium imaging correlation:

  • GCaMP expression in genetically-accessed NTSR2 populations

  • Functional imaging during neurotensin administration or behavioral tasks

  • Post-hoc antibody staining to confirm NTSR2 expression in recorded neurons

• Optogenetic/chemogenetic manipulation validation:

  • Selective expression of opsins or DREADDs in NTSR2 neurons

  • Antibody verification of manipulation tool expression

  • Correlation between receptor levels and manipulation efficacy

• Single-cell transcriptomics integration:

  • Patch-seq approaches combining electrophysiology, morphology, and transcriptomics

  • Antibody validation of NTSR2 protein expression in molecularly defined subtypes

  • Creation of integrated neuron type definitions incorporating NTSR2 expression

How can super-resolution microscopy enhance NTSR2 localization studies?

Super-resolution approaches reveal subcellular NTSR2 distribution patterns:

• Technique selection based on experimental goals:

  • STED (Stimulated Emission Depletion): For live-cell receptor dynamics

  • STORM/PALM: For precise receptor clustering analysis

  • SIM (Structured Illumination): For broader field colocalization studies

  • Expansion microscopy: For improved resolution with standard confocal equipment

• NTSR2 antibody optimization for super-resolution:

  • Evaluate signal density and specificity at super-resolution scales

  • Test directly conjugated primary antibodies to reduce linkage error

  • Optimize labeling density for single-molecule localization methods

  • Consider smaller detection probes (Fab fragments, nanobodies)

• Sample preparation refinements:

  • Thin sectioning (70-100 nm) for improved signal-to-noise

  • Specialized fixation for epitope preservation at nanoscale

  • Appropriate buffering systems for photoswitchable fluorophores

  • Drift compensation markers for prolonged acquisition

• Multi-channel super-resolution strategies:

  • Correlate NTSR2 with synaptic markers at nanoscale resolution

  • Examine receptor juxtaposition with signaling components

  • Study membrane microdomain association through clustering analysis

  • Determine relative positioning to trafficking machinery

• Quantitative analysis approaches:

  • Cluster identification and morphology characterization

  • Nearest-neighbor distance measurements

  • Ripley's K-function analysis for distribution patterns

  • Colocalization at super-resolution scale with appropriate statistics

• Dynamic studies:

  • Single-particle tracking of antibody-labeled NTSR2

  • Activity-dependent redistribution at nanoscale resolution

  • Agonist-induced clustering and internalization dynamics

  • Correlation between receptor organization and signaling efficacy

What considerations apply when using NTSR2 antibodies in human tissue samples for clinical research?

Clinical research using NTSR2 antibodies requires specific adaptations:

• Human tissue-specific validation:

  • Comprehensive testing across multiple human samples

  • Positive and negative control tissues based on established expression patterns

  • Peptide competition controls for specificity verification

  • Correlation with mRNA expression by in situ hybridization

• Post-mortem interval considerations:

  • Evaluate epitope stability across different post-mortem intervals

  • Establish detection windows for reliable results

  • Implement modified fixation protocols for partially degraded samples

  • Develop quantitative correction factors for PMI effects

• Fixation variability management:

  • Test antibody performance across fixation methods commonly used in clinical settings

  • Optimize antigen retrieval for formalin-fixed paraffin-embedded tissues

  • Establish protocol modifications for archival samples

  • Create standardized positive controls for inter-study normalization

• Disease state evaluation protocols:

  • Paired analysis of affected and unaffected tissue regions

  • Age-matched control case comparison

  • Medication effect consideration in psychiatric tissue

  • Correlation with disease-specific markers

• Ethical and regulatory compliance:

  • IRB approval for antibody validation on human samples

  • Appropriate consent documentation for tissue use

  • Blinding procedures for unbiased analysis

  • Data management compliant with human subject research standards

• Clinicopathological correlation approaches:

  • Medical record integration with NTSR2 expression data

  • Symptom severity correlation with receptor levels

  • Treatment response prediction based on receptor patterns

  • Longitudinal analysis in serial biopsy samples when available

What are robust methods for quantifying NTSR2 antibody signals across different experimental platforms?

Standardized quantification enables reliable cross-study comparisons:

• Western blot quantification approaches:

  • Establish linear dynamic range for each antibody lot

  • Include standard curves with recombinant NTSR2 protein

  • Normalize to appropriate loading controls (Na⁺/K⁺-ATPase for membrane fractions)

  • Implement total protein normalization methods

• Immunohistochemistry quantification:

  • Unbiased stereological counting for cell population analysis

  • Optical density measurements for expression level estimation

  • Standardized ROI selection protocols for regional comparisons

  • Background subtraction methods specific to each tissue type

• Fluorescence intensity analysis:

  • Implement flat-field correction for uniform illumination

  • Include calibration standards in each imaging session

  • Account for tissue autofluorescence through spectral unmixing

  • Use nuclear counterstains for cell-count normalization

• Flow cytometry approaches:

  • Establish antibody saturation concentrations

  • Include isotype and fluorescence-minus-one controls

  • Standardize gating strategies across experiments

  • Use quantitative beads for intensity calibration

• Digital image analysis workflows:

  • Automated threshold determination methods

  • Machine learning-based object recognition for complex tissues

  • Batch processing with identical parameters across samples

  • Blinded analysis to eliminate confirmation bias

• Statistical considerations:

  • Power analysis for sample size determination

  • Appropriate statistical tests for dataset characteristics

  • Multiple comparison corrections for regional analyses

  • Hierarchical analysis approaches for nested data

How can I correlate NTSR2 protein levels detected by antibodies with mRNA expression data?

Multi-level expression analysis provides deeper biological insights:

• Technical approach integration:

  • Sequential analysis workflow:

    • Perform NTSR2 immunohistochemistry

    • Document cell-specific expression patterns

    • Conduct RNAscope in situ hybridization on adjacent sections

    • Register and align images for comparative analysis

  • Combined protein-mRNA detection:

    • Implement immunofluorescence followed by in situ hybridization

    • Use spectrally distinct labels for protein and mRNA

    • Capture high-resolution z-stacks for co-localization analysis

    • Quantify relative signal intensities at cellular level

• Quantitative correlation methods:

  • Cell-by-cell correlation of protein and mRNA levels

  • Regional average comparisons across brain structures

  • Regression analysis to establish relationship models

  • Bioinformatic integration with public expression databases

• Discrepancy analysis approaches:

  • Identify populations with protein-mRNA expression mismatches

  • Investigate potential post-transcriptional regulatory mechanisms

  • Examine receptor half-life and turnover rates

  • Consider developmental timing differences in expression

• Single-cell resolution strategies:

  • Laser capture microdissection of antibody-labeled cells

  • qRT-PCR for NTSR2 mRNA quantification

  • Correlation with protein levels from parallel samples

  • Patch-seq approaches combining electrophysiology with transcriptomics

• Validation controls:

  • Use genes with known protein-mRNA correlations as standards

  • Include samples from conditions altering post-transcriptional regulation

  • Systematic analysis of multiple brain regions to identify patterns

  • Technical replicate analysis to establish method reliability

Table 1: NTSR2 Antibody Application Compatibility Matrix

Table 2: NTSR2 Expression Across Brain Regions and Development

Table 3: Troubleshooting NTSR2 Antibody Detection Issues